Login to Your Account



Other News To Note


Tuesday, April 30, 2013
• Cara Therapeutics Inc., of Shelton, Conn., and Maruishi Pharmaceutical Co. Ltd., of Osaka, Japan, said they entered a license agreement providing Maruishi exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription